Marks Group Wealth Management Inc Purchases 4,118 Shares of Cencora, Inc. $COR

Marks Group Wealth Management Inc raised its position in Cencora, Inc. (NYSE:COR) by 620.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,782 shares of the company’s stock after buying an additional 4,118 shares during the quarter. Marks Group Wealth Management Inc’s holdings in Cencora were worth $1,615,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in COR. Oakworth Capital Inc. bought a new stake in shares of Cencora during the 4th quarter valued at approximately $26,000. Elyxium Wealth LLC bought a new stake in shares of Cencora during the 4th quarter valued at approximately $27,000. Archer Investment Corp grew its holdings in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after purchasing an additional 47 shares during the last quarter. IAG Wealth Partners LLC bought a new stake in shares of Cencora during the 3rd quarter valued at approximately $30,000. Finally, Caitlin John LLC bought a new stake in shares of Cencora during the 3rd quarter valued at approximately $31,000. 97.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

COR has been the topic of several research reports. William Blair initiated coverage on shares of Cencora in a report on Tuesday, April 28th. They set a “market perform” rating on the stock. UBS Group lifted their price target on shares of Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Morgan Stanley set a $342.00 price target on shares of Cencora in a report on Friday, May 8th. Robert W. Baird decreased their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Evercore set a $360.00 price target on shares of Cencora in a report on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $380.25.

Cencora Price Performance

COR stock opened at $279.15 on Wednesday. The company has a fifty day moving average price of $291.16 and a 200-day moving average price of $329.11. The company has a market capitalization of $54.31 billion, a P/E ratio of 21.41, a PEG ratio of 1.48 and a beta of 0.59. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). The business had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. Cencora’s revenue was up 3.9% on a year-over-year basis. During the same period in the previous year, the business posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities analysts expect that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were given a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. Cencora’s payout ratio is 18.40%.

Cencora declared that its Board of Directors has initiated a share buyback program on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to reacquire up to 3.9% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.